Journal of Gastrointestinal Infections

Register      Login

VOLUME 3 , ISSUE 1 ( 2013 ) > List of Articles

BRIEF COMMUNICATION

Seroprevalence and risk factors of hepatitis B and hepatitis C virus infections among patientswith chronic liver diseases

Shikha Jain, Rupinder K Bakshi, Geeta Walia

Keywords : Hepatitis B virus, Hepatitis C virus, Hepatocellular carcinoma

Citation Information : Jain S, Bakshi RK, Walia G. Seroprevalence and risk factors of hepatitis B and hepatitis C virus infections among patientswith chronic liver diseases. J Gastrointest Infect 2013; 3 (1):61-63.

DOI: 10.5005/jogi-3-1-61

License: CC BY-SA 4.0

Published Online: 00-07-2013

Copyright Statement:  Copyright © 2013; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Introduction & Objectives: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for a substantial proportion of liver diseases worldwide. Because the two hepatotropic viruses share same modes of transmission, co-infection with the two viruses is not uncommon, especially in areas with a high prevalence of HBV infection and among people at high risk for parenteral infection. Material & Methods: This study was conducted from January- December 2011 during which 170 blood samples were collected frompatients suffering fromchronic liver diseases (CLD) (chronic hepatitis or cirrhosis) admitted in Medicine Department. Five ml venous blood sample was collected and processed in Department of Microbiology. HBsAg was detected by using Hepacard Test and anti HCV was detected by using HCV Tridot - rapid visual test (J. Mitra & Co. Ltd.). Results: Among 170 patients with CLD, HBsAg seropositivity was 28% (47/170) while anti-HCV seropositivity was 41% (70/170). Co-infection of HBsAg and anti-HCV was 3.5% (6/170). In patients with alcoholic hepatitis/ cirrhosis, seropositivity of HBsAg & anti-HCV was 19.4% & 29.0%respectivelywhile in patientswith non alcoholic chronic hepatitis/cirrhosis, it was 23.1% & 48.1% respectively. Interpretation and Conclusion: Seroprevalence of HBsAg & anti-HCV in patients with CLD was 28% and 41% respectively whereas co-infection of HBsAg & anti-HCV was 3.5%.


PDF Share
  1. Abou MA, Eltahir YM, Ali AS. Seroprevalence of hepatitis B virus and hepatitis C virus among blood donors in Nyala, South Dar Fur, Sudan. Virol J 2009;6:146.
  2. Liu Z, Hou J. Hepatitis B Virus (HBV) and hepatitis C virus (HCV) dual Infection. Int J Med Sci 2006;3(2):57-62.
  3. Chowdhury A. Epidemiology of hepatitis B virus infection in India. Hep BAnnual 2004;1:17-24.
  4. Chakravarti A, Verma V. Prevalence of hepatitis C and B viral markers in patients with chronic liver disease: a study from Northern India. Indian J Med Microbiol 2005;23(4):273-4.
  5. Seyed-Moayed A, Peyman A, Mohammad RZ. Hepatitis C virus in Iran: epidemiology of an emerging infection. Arch Iranian Med 2005;8(2):84-90.
  6. Bukhtiari N, Hussain T, Iqbal M, Malik AM, Qureshi AH, Hussain A. Hepatitis B and C single and co-infection in chronic liver disease and their effect on the disease pattern. J Pak Med Assoc 2003;53(4):136-40.
  7. Devi KS, Singh NB, Mara J, Singh TB, Singh YM. Seroprevalence of hepatitis B virus and hepatitis Cvirus among hepatic disorders and injecting drug users in Manipur- a preliminary report. Indian J Med Microbiol 2004;22(2):136-7.
  8. Singh V, Katyal R, Kochhar RK, Bhasin DK, Aggarwal RP. Study of hepatitis B and C viral markers in patients of chronic liver disease. Indian J Med Microbiol 2004;22(4):269-70.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.